Long Arg3 IGF-I analogue

IGF-1 LR3

IGF-1 LR3 is an extended IGF-I analogue with an Arg3 substitution. The cited study examines folding and binding of defined IGF-I analogues.

Quantity per vial

Select variantCompare prices and choose a variant to set the quantity and add it to your quote.

Subtotal excludes freight and taxes. Availability and final terms are confirmed in the quote. Commercial and shipping terms

Mechanism and findings

In vitro · Study formulation · IGF analogue folding and cell-based assays

Folding and binding

The study compared native and misfolded IGF analogues, including Long-[Arg3]IGF-I; isomer-specific results are not batch identity verification.

Milner et al., 1995 →

Literature findings; refer to the model and formulation studied.

Mechanism of action

IGF-1 LR3 — long arg3 igf-i analogue. The literature identity must be matched to the documented chemical form and composition of the supplied material.

The Arg3 substitution and N-terminal extension were examined for oxidative folding and interactions with the IGF-I receptor and IGF-binding proteins. The work separates isomers with different disulfide bonds; their properties must not be presented as one result for any LR3 preparation.

  • IGF-1 receptor and binding proteins

Milner et al., 1995

Studied findings 1
In vitro · Study formulation

Folding and binding

IGF analogue folding and cell-based assays

The study compared native and misfolded IGF analogues, including Long-[Arg3]IGF-I; isomer-specific results are not batch identity verification.

View context
Study design
Original-study abstract; experimental design described in linked source
Sample scope / arm
Not extracted; consult original study
Comparator
See original-study context
Experimental context (not instructions for use)
Abstract-level extraction; full methods and tables still require review.
Source section / table / abstract
Abstract

Evidence concerns the studied material and model, not the supplied BLOPEP batch.

Milner et al., 1995

Sources and studies 1
  1. Mutations in the B-domain of insulin-like growth factor-I influence the oxidative folding to yield products with modified biological properties.

    Milner SJ, Francis GL, Wallace JC, Magee BA, Ballard FJ · 1995 · The Biochemical journal

    DOI: 10.1042/bj3080865

Specifications and packaging

Nominal variant content; analytical results belong to the documented batch.

Material type
Biologic material

Quality and analyses

Review specifications, analytical results and documentation for published batches.

Purity
>99%
Type
Declared specification

Published batches

Batch results have not yet been published on this page.

Storage

Consult the specific conditions in the supplied material documentation.

Delivery and commercial terms

Freight, timing and import terms will be confirmed in the quote for the selected destination.